Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - CAREFUSION Corp | d479777d8k.htm |
| EX-99.1 - NEWS RELEASE - CAREFUSION Corp | d479777dex991.htm |
 Updated Fiscal
2013 Financial Guidance
February 7, 2013
Exhibit 99.2 |
 ©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
Forward-Looking Statements
financial guidance, which are forward-looking statements addressing expectations,
prospects, estimates and other matters that are dependent upon future events or
developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected, anticipated or implied. The
most significant of these uncertainties are described in CareFusion’s Form
10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include
(but are not limited to) the following: we may be unable to effectively enhance our existing
products or introduce and market new products or may fail to keep pace with advances in
technology; we are subject to complex and costly regulation; cost containment efforts of our customers,
purchasing groups, third-party payers and governmental organizations could adversely
affect our sales and profitability; current economic conditions have and may continue
to adversely affect our results of operations and financial condition; we may be unable to realize any benefit
from our cost reduction and restructuring efforts and our profitability may be hurt or our
business otherwise might be adversely affected; we may be unable to protect our
intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with
our products and/or our quality system could lead to the filing of adverse event reports,
recalls or safety alerts and negative publicity and could subject us to regulatory
actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the
requirements of the amended consent decree may have an adverse effect on our business; and our
success depends on our key personnel, and the loss of key personnel or the transition
of key personnel, including our chief executive officer, could disrupt our business. This presentation reflects
management’s views as of February 7, 2013. Except to the limited extent required by
applicable law, CareFusion undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
“Safe
Harbor”
Statement
under
the
Private
Securities
Litigation
Reform
Act
of
1995:
This
presentation
contains
our
fiscal
2013 |
 ©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
Fiscal 2013 Guidance
February 7, 2013
FY13 Guidance
Total Revenue (constant currency)
1 –
3%
Medical Systems Revenue (constant currency)
1 –
3%
Procedural Solutions Revenue (constant currency)
3 –
5%
Adjusted Operating Margin
¹
20.0%+
Adjusted Effective Tax Rate
¹
27 –
29%
Adjusted Diluted EPS From Continuing Operations
¹
$2.11 –
$2.21
Diluted Weighted Average Shares Outstanding
²
~221M
Operating Cash Flow
$525 –
$575M
Capital Expenditures
~$110M
1
Adjusted
amounts
are
non-GAAP
financial
measures.
These
measures
exclude
amortization
of
acquired
intangible
assets,
nonrecurring
restructuring
and
acquisition
integration
charges,
and
the
tax
effects
of
these
items.
A
GAAP
to
non-GAAP
reconciliation
can
be
found
in
the
company’s
Q2FY13
earnings
release,
which
was
furnished
to
the
SEC
on
Form
8-K
on
February
7,
2013
and
is
posted
on
CareFusion’s
website
at
www.carefusion.com
under
the
Investors
tab.
The
Form
8-K
also
includes
a
discussion
of
the
reasons
why
management
believes
that
the
presentation
of
non-GAAP
financial
measures
provides
useful
information
to
investors
regarding
the
company’s
financial
condition
and
results
of
operations.
2
On February 10, 2012 CareFusion announced a $500M share repurchase program. Outlook
for diluted weighted average shares outstanding reflects the impact of expected repurchases
during fiscal 2013. |